S-40503
Also known as: S-40503, S40503
Developed for bone rather than muscle — the one SARM whose research goal was osteoporosis, with a bone effect that outpaced its anabolic one.
Substance family
Non-steroidal compounds binding the same androgen receptor as testosterone, but favouring muscle and bone over prostate and hair. The selectivity is real; the suppression of the body's own production is not avoided by it. None is approved anywhere.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance causes
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Human clinical data
MedicalDose
Does not exist
Frequency
—
Cycle length
—
Developed by Kaken Pharmaceutical for osteoporosis. Rat studies only; no human trial was conducted.
Grey market practice
Not a recommendationDose
Rarely available; figures unreliable
Frequency
—
Cycle length
—
S-40503 is uncommon on the grey market and no established dosing pattern exists. Products sold under this name are particularly likely to be something else.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
The bone data is from rats, and bone takes years in humans
Countermeasure
The preclinical results on bone mineral density were the reason for the programme and are genuinely interesting. But bone remodelling in a person happens over years, not the weeks a rat study runs. Extrapolating a rodent bone result to a human skeleton across an 8-week cycle is not a supportable inference.
Problem
Suppression despite the bone framing
Countermeasure
Being developed for osteoporosis does not make it non-androgenic. It activates the androgen receptorandrogen receptorThe docking site in the cell that androgens bind to in order to have any effect. and suppresses the axis like the rest of the category. Bloodwork before and after, and a PCTPCTThe protocol after a cycle intended to restart the body's own testosterone production. plan.
Problem
Rarely available means high substitution risk
Countermeasure
Because genuine S-40503 is scarce, products carrying the name are more likely than usual to contain a cheaper, more available SARMSARMA non-steroidal compound that binds the androgen receptor with claimed tissue selectivity. instead. That is a documented pattern in this market for obscure compounds.
Problem
Falling HDL
Countermeasure
As with the other oral SARMsSARMsA non-steroidal compound that binds the androgen receptor with claimed tissue selectivity.. Cardio, omega-3 and citrus bergamot help at the margin; a lipid panel decides whether to continue.
Overview
S-40503 is worth including because it shows what SARMs were actually developed for, which is easy to lose sight of in a bodybuilding context.
Kaken Pharmaceutical developed it as an osteoporosis treatment. The goal was to strengthen bone in patients — often older women — without the virilising effects that make testosterone unusable for that purpose.
Mechanism of Action
A non-steroidal androgen receptor agonist with unusually strong preference for bone tissue. In rat studies it increased bone mineral density substantially, with a comparatively modest effect on muscle and minimal prostate stimulation.
That profile is the inverse of what the bodybuilding market wants, and it is why S-40503 never became popular despite being a genuine research compound.
Why the Bone Angle Rarely Transfers
The compound is occasionally suggested for joint and connective tissue support during heavy training, on the reasoning that stronger bone helps when strength rises faster than the passive structures can adapt.
The reasoning has a real basis, and the evidence does not support acting on it. Bone remodelling operates on a timescale of years in humans. A rat study measuring bone density over weeks does not translate to a person running an eight-week cycle, and no human has been measured on this compound at all.
Anyone genuinely concerned about connective tissue during a strength phase has better-founded options: progressive loading, adequate protein, glycine and collagen, vitamin D and calcium status, and above all not letting strength outrun tendon adaptation.
Honest Placement
Among SARMs: obscure, weakly anabolic, preclinical only, and hard to obtain genuinely. The interest it holds is historical and conceptual rather than practical — it is a clear illustration that this class was designed for medicine, and that the properties which made it attractive to researchers are not the properties the grey market values.
Side Effects & Risks
- Suppression of the body's own production
- Falling HDL, rising LDL
- Fatigue and low mood, largely downstream of suppression
- High risk of substitution given its scarcity
- No manufacturing oversight
Blood Work & Monitoring
- Total and free testosterone, LH, FSH — before, during and after
- Lipid profile (LDL, HDL, triglycerides)
- Liver values (ALT, AST, GGT)
- Vitamin D and calcium — if bone health is genuinely the concern, these are the values that matter and can be acted on
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Not approved; FDA warning applies to the SARM category |
| EU / UK | No marketing authorisation |
| Most other jurisdictions | Unregulated grey area |
| Competitive sport | Prohibited at all timesListed by WADA under S1.2. |